The latest findings from five studies presented at the ESMO Congress 2021 help cut short the debate on the safety and efficacy of COVID vaccines in cancer patients and re-affirm ESMO’s recommendations for early vaccination of this high-priority population, as outlined in the ESMO ten statements, which were updated in April 2021. Patients with cancer or a history of cancer were under-represented in the initial pivotal vaccine trials, despite mortality due to COVID-19 is higher in this group compared with the general population.

Read more on the ESMO website here